Boston B
Cancer. 1976 Jul;38(1):49-52. doi: 10.1002/1097-0142(197607)38:1<49::aid-cncr2820380109>3.0.co;2-6.
Despite conventional therapy, including surgery and radiation, 5-year survival for invasive thymoma remains poor. Chemotherapeutic agents, including cisdiamminedichloroplatinum, prednisone, adriamycin and nitrogen mustard-vincristine-vinblastine-procarbazine, and bleomycin-adriamycin-CCNU-vincristine have produced short-term remissions. In view of the small number of cases seen in any one institution, a cooperative study to evaluate chemotherapeutic efficacy in malignant thymoma would seem worthwhile.
尽管采用了包括手术和放疗在内的传统治疗方法，浸润性胸腺瘤的5年生存率仍然很低。化疗药物，包括顺铂、泼尼松、阿霉素以及氮芥-长春新碱-长春花碱-丙卡巴肼，还有博来霉素-阿霉素-洛莫司汀-长春新碱，都曾产生过短期缓解。鉴于单个机构所诊治的病例数量较少，开展一项评估恶性胸腺瘤化疗疗效的合作研究似乎是值得的。
